Gland Pharma Limited — Q3 FY25
Gland Pharma's Q3 FY25 consolidated revenue was INR 1,384 crore, with EBITDA margin improving 100 bps YoY to 26%.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Cenexi positive EBITDA by Q4 FY25
Cenexi targets positive EBITDA in Q4 FY25, supported by new ampoule line commercial production starting January 2025.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY25
Biologics CDMO initial benefits from Q1 FY26
The Dr. Reddy's biologics CDMO collaboration is expected to generate initial financial benefits from Q1 FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1